DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA
DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been treated in a multicenter Phase 2 trial…
Read More...
Read More...